Moshkevich Solomon sold $906K of NTRA

Moshkevich Solomon (PRESIDENT, CLINICALDIAGNOSTICS) sold 3,410 shares of Natera, Inc. (NTRA) at an average of $265.58 ($259.98–$268.70, $0.91M total) across 7 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Moshkevich Solomon
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, share count, and the fact it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This provides a fresh insider-selling datapoint, but it is not tied to earnings, guidance, or regulatory/product events in the text.

03

What to watch

Traders may focus on whether multiple insiders are selling concurrently or whether the sale coincides with other company-specific catalysts, which are not present in this text.

Relevance 4/10Novelty 5/10Timing: filed Aug 5, transaction dated Aug 3

Background

The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera Form 4 shows President, Clinical Diagnostics Moshkevich Solomon sold $905,626 of NTRA shares via a 10b5-1 plan on Aug 3.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a primary-source Form 4 and the transaction size is moderate, but the presence of a pre-arranged 10b5-1 plan reduces interpretive signal.

Market effects

Minimal; insider sales under 10b5-1 typically do not reset sector expectations for diagnostics/biotech.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price impact could be negligible.

Key entities

  • Natera, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Moshkevich Solomon

    President, Clinical Diagnostics; sold 3,410 shares of NTRA on Aug 3 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.